Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
The small-molecule oncology player zeroes in on its first commercial opportunity.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, while Abbvie and Astrazeneca have added to their budgets.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.